Key result
Nesiritide is an intravenous vasodilator used for acutely decompensated heart failure, with ongoing trials exploring its potential benefits across various clinical situations.
Answers are grounded in this paper and cite their sources.
Nesiritide is an established treatment for acutely decompensated heart failure, with ongoing trials investigating its potential in other clinical scenarios.
Nesiritide, recombinant human B-type natriuretic peptide, is an intravenous vasodilator that is used to treat acutely decompensated heart failure. In addition to its modest diuretic and natriuretic properties, nesiritide reduces intracardiac filling pressures, increases cardiac index and improves symptoms. Long-term safety data are accruing, and a number of ongoing clinical trials will explore the potential benefit of nesiritide in a variety of clinical situations: peri-operative cardiac surgery, serial out-patient infusions, continuous out-patient or pretransplant infusions, and infusions in patients with pulmonary hypertension, bronchospasm, renal insufficiency, and acute coronary syndromes. Alternative delivery methods also are under development.
No takes yet. Share an insight, caveat, or question.
Hobbs et al. (2005) conducted a review in acutely decompensated heart failure. Nesiritide was evaluated. Nesiritide is an intravenous vasodilator used for acutely decompensated heart failure, with ongoing trials exploring its potential benefits across various clinical situations.
Synapse has enriched 10 related papers. Consider them for comparative context: